华大基因(300676) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥1,042,166,389.29, representing a 9.19% increase compared to the same period last year[3] - The net profit attributable to shareholders was -¥27,165,209.53, a decrease of 80.92% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,276,537.39, a decrease of 74.17% compared to the previous year[3] - For the first three quarters of 2025, the company achieved operating revenue of RMB 267,363.87 million, a year-on-year decrease of 5.39%[15] - The net profit attributable to shareholders for the same period was RMB -2,138.70 million, an increase of 82.78% year-on-year[15] - In Q3 2025, the company reported operating revenue of RMB 104,216.64 million, a year-on-year growth of 9.19%[15] - Total revenue for the current period is ¥2,673,638,742.11, a decrease of 5.37% from ¥2,825,935,926.99 in the previous period[30] - The net profit for the current period is -26,230,892.14, compared to -124,180,426.78 in the previous period, showing a significant improvement[31] - Operating profit for the current period is -35,804,257.97, an improvement from -119,699,288.76 in the previous period[31] - Total comprehensive income for the current period is -63,301,430.15, compared to -154,305,996.91 in the previous period, reflecting a reduction in losses[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,301,377,285.05, down 1.92% from the end of the previous year[3] - Total current assets decreased to ¥6,530,214,262.62 from ¥6,875,791,256.55, reflecting a decline of 5.02%[28] - Total non-current assets increased to ¥5,771,163,022.43 from ¥5,666,495,138.08, showing a growth of 1.85%[28] - Total liabilities decreased to ¥2,929,583,566.20 from ¥3,270,676,576.56, a reduction of 10.43%[28] - The company's total equity increased to ¥9,371,793,718.85 from ¥9,271,609,818.07, reflecting a growth of 1.08%[29] Cash Flow - The company's cash flow from operating activities was -¥436,673,090.75, a decrease of 205.77% compared to the same period last year[3] - Cash flow from operating activities shows a net outflow of -436,673,090.75, compared to -142,812,352.08 in the previous period, indicating a worsening cash flow situation[32] - The company received cash from investment activities totaling 4,754,090,112.22, compared to 7,661,136,503.58 in the previous period, indicating a decrease in investment inflows[32] - The net cash flow from financing activities is 180,044,633.76, a recovery from -316,812,088.02 in the previous period[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,903[10] - As of the report date, the controlling shareholder, BGI Holdings, pledged 10.375 million shares, accounting for 79.18% of its holdings and 24.80% of the total share capital[20] - The shareholder, Shenzhen Shenghua Investment, reduced its holdings by 1.2507 million shares, representing 0.2990% of the total share capital, as part of a planned reduction of up to 6.2748 million shares[23] - BGI Holdings transferred 16.7327 million shares at a price of 44.10 yuan per share, totaling approximately 738 million yuan, reducing its stake from 38.17% to 31.32%[24] Business Segments - The reproductive health business generated operating revenue of RMB 643 million, down 28.4% compared to RMB 899 million in the same period of 2024[17] - The non-invasive prenatal genetic testing business saw a revenue decline of approximately 36% year-on-year[17] - Revenue from the hereditary disease clinical diagnosis series in the tertiary prevention business grew by approximately 17% year-on-year[17] - The oncology and chronic disease prevention business achieved revenue of 358 million yuan, a decrease of 8.8% compared to 393 million yuan in the same period of 2024[18] - The infection prevention business reported revenue of 75 million yuan, a year-on-year increase of 41.7% from 53 million yuan in 2024, driven by the development of a pathogen sequencing platform and automation systems[18] - The multi-omics and synthesis business generated revenue of 452 million yuan, remaining stable compared to the previous year, with single-cell sequencing revenue growing approximately 93%[18] - The precision medicine testing comprehensive solution business achieved revenue of 1.124 billion yuan, an increase of 11.2% from 1.010 billion yuan in 2024, due to accelerated local clinical application and successful overseas market expansion[19] Expenses - The sales expenses decreased by 17.73%, management expenses decreased by 17.76%, and R&D expenses decreased by 16.38% during the reporting period[15] - Research and development expenses decreased to ¥332,812,703.86, a reduction of 16.43% compared to ¥398,014,771.10 in the previous period[30] Other Financial Metrics - The basic earnings per share were -¥0.0653, an increase of 81.08% year-on-year[3] - The weighted average return on equity was -0.29%, an increase of 1.14% compared to the previous year[3] - The company recorded an increase of RMB 82.11 million in credit impairment losses compared to the same period last year due to extended customer payment cycles[16] - The company incurred a tax expense of -19,791,439.13, compared to -2,842,029.91 in the previous period, indicating a higher tax burden despite losses[31]